Keyword: UCB

UCB is sponsoring an effort to create a clinical care standard for women with inflammatory bowel disease (IBD) before, during and after pregnancy.

Biogen and UCB are already rumored to be eyeing an Acorda buyout. But one analyst thinks a host of other major players could join their ranks.

Earlier this month, reports said Acorda could be scouting buyers. And now, rumors are swirling as to who those potential bidders might be.

Amgen debuted a Prolia TV ad with longtime spokesperson Blythe Danner, just weeks after a setback for its next-gen osteoporosis med romosozumab.

The drive to digital health runs straight through pharma territory, so it’s not surprising that many traditional drug companies are working on solutions.

The world's best-selling drug, AbbVie's Humira, isn’t worth its current net price—and isn’t as good at its job as two potential competitors. That’s ICER's conclusion after reviewing rheumatoid arthritis meds.

A self-injection pen prefilled with Brussels-based UCB’s Cimzia (certolizumab pegol) has been made available this week in the U.K. after a positive opinion from the EMA.

It’s a great day for Belgium’s UCB pharma, thanks to a U.S. District Court patent ruling. In fact, it’s one of the company's best days in years.

A team of JAMA authors urged the FDA in 2014 to add “black box” warnings to dopamine agonists, linking the Parkinson's meds to pathological gambling, compulsive shopping and sexual obsessions. Now, consumer watchdog Public Citizen is upping the ante with a citizen petition to the agency, citing more than 80 studies supporting its claims.

@FiercePharma: Trending: Baxter fesses up to irregularities in China. Story | Follow @FiercePharma @EricPFierce: ICYMI: Teva confronting tough time, sooner than later. Patent loss and soft quarter...